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Attenuated viral vaccines can be generated by targeting essential pathogenicity factors. We report here the rational
design of an attenuated recombinant coronavirus vaccine based on a deletion in the coding sequence of the non-
structural protein 1 (nsp1). In cell culture, nsp1 of mouse hepatitis virus (MHV), like its SARS-coronavirus homolog,
strongly reduced cellular gene expression. The effect of nsp1 on MHV replication in vitro and in vivo was analyzed
using a recombinant MHV encoding a deletion in the nsp1-coding sequence. The recombinant MHV nsp1 mutant grew
normally in tissue culture, but was severely attenuated in vivo. Replication and spread of the nsp1 mutant virus was
restored almost to wild-type levels in type I interferon (IFN) receptor-deficient mice, indicating that nsp1 interferes
efficiently with the type I IFN system. Importantly, replication of nsp1 mutant virus in professional antigen-presenting
cells such as conventional dendritic cells and macrophages, and induction of type I IFN in plasmacytoid dendritic cells,
was not impaired. Furthermore, even low doses of nsp1 mutant MHV elicited potent cytotoxic T cell responses and
protected mice against homologous and heterologous virus challenge. Taken together, the presented attenuation
strategy provides a paradigm for the development of highly efficient coronavirus vaccines.
Citation: Zu¨st R, Cervantes-Barraga´n L, Kuri T, Blakqori G, Weber F, et al. (2007) Coronavirus non-structural protein 1 is a major pathogenicity factor: Implications for the
rational design of coronavirus vaccines. PLoS Pathog 3(8): e109. doi:10.1371/journal.ppat.0030109
Introduction
Coronaviruses are vertebrate pathogens mainly associated
with respiratory and enteric diseases [1]. They can cause
severe diseases in livestock animals and lead thereby to high
economic losses. In humans, coronavirus infections manifest
usually as mild respiratory tract disease (common cold) that
may cause more severe symptoms in elderly or immune-
compromised individuals [2,3]. In 2002–2003, the appearance
of severe acute respiratory syndrome (SARS), caused by a
formerly unknown coronavirus (SARS-CoV), exempliﬁed the
potential of coronaviruses to seriously affect human health
[4–7]. The frequent detection of SARS-like coronaviruses in
horseshoe bats (Rhinolophus sp.) and the broad range of
mammalian hosts that are susceptible to SARS-CoV infection
may facilitate a potential reintroduction into the human
population [8]. Therefore, the development of efﬁcacious
coronavirus vaccines is of high medical and veterinary
importance.
Effective vaccines controlling virus spread and disease are
available for a number of infections, such as smallpox,
poliomyelitis, measles, mumps, rubella, inﬂuenza, hepatitis
A, and hepatitis B [9,10]. Some of these vaccines consist of
virus subunits or inactivated virus preparations that mainly
induce the production of pathogen-speciﬁc antibodies. In
contrast, live attenuated vaccines consist of replication-
competent viruses that induce broad cellular and humoral
immune responses without causing disease [10]. The most
prominent live attenuated vaccines are vaccinia virus [11],
poliovirus [12], and yellow fever virus (YF-17D) [13]. Despite
their documented efﬁcacy, it is still not fully understood why
and how successful vaccines work [10,14]. However, recent
concepts in immunology provide a link between innate and
adaptive immune responses and suggest that the quality,
quantity, and longevity of adaptive immune responses is
determined very early after infection or vaccination [14]. Of
major importance are professional antigen-presenting cells
(pAPCs) such as dendritic cells (DCs) and macrophages, which
play a major role in (i) sensing pathogen-associated molecular
patterns, (ii) inducing innate immune responses, and (iii)
shaping the upcoming adaptive immune response. Efﬁcient
live attenuated vaccines should therefore not only lack
signiﬁcant pathogenicity, but should also deliver antigens to
pAPCs and activate the innate immune system.
Notably, the majority of currently available attenuated
vaccines have been derived empirically. Given the recent
proceedings in the areas of virus reverse genetics and virus–
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host interactions, the time should be ripe for more rational
approaches in vaccine development. An attractive strategy is
to target virally encoded pathogenicity factors, such as
interferon (IFN) antagonists [15], to attenuate virulence while
retaining immunogenicity. This concept has been proposed
for the generation of live attenuated inﬂuenza virus vaccines
encoding altered NS1 proteins [16,17].
Our rudimentary knowledge on coronavirus-encoded
pathogenicity factors is reﬂected by the fact that only a few
putative coronaviral pathogenicity factors have been identi-
ﬁed and that functional analyses are still limited to the
description of in vitro effects [18–20]. For a number of
reasons, the non-structural protein 1 (nsp1) is of particular
interest in this context. First, coronaviruses are positive-
stranded RNA viruses, and the replicase-encoded nsps are
expressed from the viral genomic RNA immediately after
virus entry by translation of two large polyproteins. nsp1 is
encoded at the 59 end of the replicase gene and is therefore
the ﬁrst mature viral protein expressed in the host cell
cytoplasm [21]. Second, a recent in vitro study suggests that
SARS-CoV nsp1 may be associated with host cell mRNA
degradation and may counteract innate immune responses
[18]. Finally, nsp1 is encoded by all mammalian coronaviruses
known to date (coronavirus groups 1, 2a, and 2b) [22], and
recent structural data on SARS-CoV (group 2b) nsp1 suggest
functional similarities to mouse hepatitis virus (MHV; group
2a) nsp1 [23].
Using a reverse genetics approach, we show here that nsp1
is a major pathogenicity factor. Recombinant MHV mutants
encoding a deletion in nsp1 replicated as efﬁciently as wild-
type virus in cell culture, but displayed an unprecedented
degree of attenuation in mice. Interference with the type I
IFN system appears to be the dominant mode of action of
murine coronavirus nsp1. Vaccination with the nsp1 mutant
virus elicited efﬁcient memory cytotoxic T cell responses and
protected against homologous and heterologous virus in-
fections. Our study will pave the way for the generation of
novel coronavirus vaccines based on modiﬁed coronavirus
replicase genes.
Results
Transient nsp1 Expression Affects Cellular Gene
Expression
We assessed several replicase-encoded nsps of MHV (strain
A59), SARS-CoV, and human coronavirus 229E (HCoV-229E)
for their ability to interfere with host cell gene expression.
Using transient gene expression studies, we found that MHV-
A59, SARS-CoV, and HCoV-229E nsp1 signiﬁcantly reduced
luciferase reporter gene expression under the control of IFN-
b, IFN-stimulated response element (ISRE), and SV40
promoters (Figure 1). This is consistent with a recent report
suggesting that SARS-CoV nsp1 induces general host cell
mRNA degradation [18]. Nevertheless, it should be noted that
the nsp1-mediated reduction in reporter protein expression
appeared more robust for ISRE and SV40 than for IFN-b
promoter-driven expression. Our data also support the
hypothesis that MHV encodes a SARS-CoV nsp1 homolog
that displays the same function [23]. Although comparative
sequence analyses suggest that nsp1 of group 2a/2b corona-
viruses (e.g., MHV and SARS-CoV, respectively) and the nsp1
of group 1 coronaviruses (e.g., HCoV-229E) may belong to
different protein families [22,23], we also observed reduced
reporter gene expression in HCoV-229E nsp1-transfected
cells (Figure 1). Whether functional similarities may exist
between nsp1 molecules encoded by coronaviruses of differ-
ent phylogenetic lineages remains to be established in future
studies. Importantly, our data also revealed that reporter
gene expression from all tested promoters was not affected
when C-terminally truncated MHV nsp1 molecules were
tested (Figure 1).
Generation of the MHV nsp1 Deletion Mutant
To assess the role of nsp1 in the context of virus
replication, we constructed a recombinant MHV encoding a
truncated nsp1 protein using our reverse genetic system [24].
Based on the results shown in Figure 1, we decided to delete
MHV nucleotides (nts) 829–927 (99 nts). In the resulting
mutant virus, MHV-nsp1D99, the replicase gene start codon,
the translational reading frame, and the residues required for
proteolytic release of nsp1 from the replicase polyprotein
were maintained (Figure 2A). As reported for a set of similar
MHV mutants by Brockway et al. [25], viral growth and peak
titers of MHV-nsp1D99 in murine 17Clone1 cells were
indistinguishable from that of wild-type virus (Figure 2B).
To assess the stability of the recombinant MHV-nsp1D99, we
analyzed the nsp1-coding region by RT-PCR sequencing after
seven passages in tissue culture and no nucleotide changes
were detected (unpublished data).
Infection of conventional DCs (cDCs) is an early and crucial
event for the generation of protective antiviral immunity
[26]. MHV productively infects cDCs and activates plasmacy-
toid DCs (pDCs) to generate a ﬁrst wave of protective type I
IFN [27]. To assess whether the mutant MHV-nsp1D99 has
retained the ability to infect pAPCs, peritoneal macrophages
(Figure 2C), bone marrow–derived CD11cþ cDCs (Figure 2D),
and splenic, FACS-sorted CD11cþ cDCs (Figure 2E) were
exposed to MHV-nsp1D99 and wild-type control virus.
Similar to replication kinetics in cell lines (Figure 2B),
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Author Summary
Prevention of viral diseases by vaccination aims for controlled
induction of protective immune responses against viral pathogens.
Live viral vaccines consist of attenuated, replication-competent
viruses that are believed to be superior in the induction of broad
immune responses, including cell-mediated immunity. The recent
proceedings in the area of virus reverse genetics allows for the
rational design of recombinant vaccines by targeting, i.e.,
inactivating, viral pathogenicity factors. For coronaviruses, a major
pathogenicity factor has now been identified. The effect of
coronavirus non-structural protein 1 on pathogenicity has been
analyzed in a murine model of coronavirus infection. By deleting a
part of this protein, a recombinant virus has been generated that is
greatly attenuated in vivo, while retaining immunogenicity. In
particular, the mutant virus retained the ability to replicate in
professional antigen-presenting cells and fulfilled an important
requirement of a promising vaccine candidate: the induction of a
protective long-lasting, antigen-specific cellular immune response.
This study has implications for the rational design of live
attenuated coronavirus vaccines aimed at preventing coronavirus-
induced diseases of veterinary and medical importance, including
the potentially lethal severe acute respiratory syndrome.
MHV-nsp1D99 showed no signiﬁcant growth defect in
primary pAPCs (Figure 2C–2E), indicating that the deletion
of nsp1 did not alter the pronounced tropism of MHV for
cDCs and macrophages.
Deletion in nsp1 Confers Strong Attenuation In Vivo
MHV-A59 is a hepatotropic and neurotropic virus that can
cause acute hepatitis and encephalitis. Following intraper-
itoneal infection, virus replication is ﬁrst detectable in spleen
and liver, followed by virus spread to other organs, including
the central nervous system. Hepatitis is the ﬁrst clinical sign
of disease, accompanied by elevated liver enzyme values in
serum. Associated with the appearance of cytotoxic T cell
responses approximately at day 5 post infection (p.i.), virus
titers usually decline and are no longer detectable after day 7
p.i. Infections with a high dose ( 5 3 106 pfu, intra-
peritoneal) may, however, occasionally result in fatality. To
evaluate the importance of nsp1 for virus replication and
viral pathogenicity in vivo, C57BL/6 mice were infected
intraperitoneally with different doses of wild-type MHV or
MHV-nsp1D99. Both viruses replicated in the spleen, whereby
MHV-nsp1D99 titers were consistently lower than wild-type
virus titers (Figure 3A). Furthermore, MHV-nsp1D99 was
rapidly cleared and not detectable after day 2 p.i. (Figure 3A).
Wild-type, but not mutant virus, was detectable in the liver at
low and intermediate dose (50 pfu and 5,000 pfu, respectively)
(Figure 3B). When high virus doses (53 106 pfu) were applied,
MHV-nsp1D99 eventually reached the liver at day 2 p.i., but
was not detectable at later time points (Figure 3B). MHV-
nsp1D99 was not detectable in other non-hematopoietic
organs, such as lung and central nervous system (unpublished
data). Mice infected with wild-type virus showed acute liver
disease with elevated liver enzyme values in serum. Further-
more, after high dose infection with wild-type virus (53 106
pfu), a signiﬁcant weight loss that peaked at approximately
10%–15% at day 4 was observed (Figure 3E). In contrast, mice
infected with the nsp1 mutant virus remained healthy after
low, intermediate, or high dose infections. Even at the highest
dose applied (53 106 pfu), MHV-nsp1D99–infected mice did
not lose weight (Figure 3E), and no elevated liver enzyme
values were detected in the serum (Figure 3C). This
observation correlated well with the absence of hepatocyte
necrosis and parenchymal inﬂammation following MHV-
nsp1D99 infection (Figure 3D). To further assess the
attenuation of the MHV nsp1 mutant, mice were infected
intracranially with 200 pfu and 20,000 pfu of MHV-nsp1D99
Figure 1. Coronavirus nsp1 Reduces Cellular Gene Expression
(A–C) 293 cells were transfected with p125-Luc reporter plasmid ([A, B];
IFN-b promoter), or p(9–27)4tkD(39)lucter reporter plasmid ([C]; ISRE
promoter) and cotransfected with pRL-SV40, and an expression plasmid
encoding a full-length coronavirus nsp1 of HCoV-229E, SARS-CoV, or
MHV, or a truncated MHV nsp1 variant (49-nt or 100-nt 39 end
truncations, respectively). At 8 h post transfection, cells were treated
with viral single-stranded RNA containing 59 triphosphates (A) or
poly(I:C) (B), or IFN-a (C), and 16 h later luciferase activity was measured.
Firefly luciferase activity was normalized to renilla luciferase activity and
indicated as fold induction compared to that of control plasmid-
transfected cells (control).
(D) 293 cells were transfected with pRL-SV40 and the indicated
expression plasmids. Then, 24 h post transfection, luciferase activity
was measured. Results represent the mean 6 SD of at least four
independent experiments. Statistical analysis was performed using
paired Student’s t-test (***, p , 0.001; **, p , 0.01; *, p , 0.05; n.s.
(not significant), p . 0.05).
doi:10.1371/journal.ppat.0030109.g001
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or MHV-A59. All mice infected with 200 pfu survived for at
least 30 d (unpublished data). Mice infected with 20,000 pfu of
MHV-A59 succumbed to the infection, whereas mice infected
with 20,000 pfu of MHV-nsp1D99 survived and showed no
signs of clinical disease (Figure 3F). Collectively, these data
demonstrate that MHV-nsp1D99 is strongly attenuated in
vivo, but has retained the ability to replicate in secondary
lymphoid organs, such as the spleen.
Effect of nsp1 on Innate Immune Responses
We have previously shown that pDCs are the major source
of IFN-a in the early stages of MHV infection and that type I
IFN responses in CD11cþ cDCs are only weakly triggered by
MHV [27]. To test whether nsp1 has an inﬂuence on the
induction of IFN-a, we infected both cDCs and pDCs with
MHV-nsp1D99 or wild-type MHV. Both viruses elicited rapid
and high IFN-a production in Flt3-L–differentiated bone
marrow–derived pDCs (Figure 4A) and FACS-sorted primary
pDCs (Figure 4B). Furthermore, both wild-type and mutant
MHV elicited only a late and weak IFN-a production in cDCs
(Figure 4A and 4B). These results suggest that nsp1 does not
affect the induction of type I IFN. To assess a potential
impact of nsp1 on type I IFN signaling and antiviral effector
mechanisms in target cells that efﬁciently support MHV
replication, cDCs and macrophages were pretreated with
different dosages of IFN-a and infected with MHV-nsp1D99
or wild-type MHV. In cDCs, IFN-a treatment had a
comparable effect on the replication of both MHV-nsp1D99
and the wild-type control virus (Figure 4C). However,
replication of MHV-nsp1D99 was, in a dose-dependent
manner, more vulnerable to IFN-a treatment in macrophages
(Figure 4D), suggesting that nsp1 might counteract IFN
signaling and/or the antiviral activities of IFN-induced
effector proteins.
Indeed, in vivo experiments in type I IFN receptor-
deﬁcient (IFNAR/) mice [28] strongly support this inter-
pretation. Infection of IFNAR/ mice with wild-type MHV
led to high titers in all tested organs (Figure 5A–5D),
indicating that signals transmitted via the IFNAR are crucial
for preventing uncontrolled spread of the virus [27].
Surprisingly, the severe attenuation of MHV-nsp1D99 in
wild-type 129Sv mice was not present in IFNAR/ mice
(Figure 5A–5D). Replication of MHV-nsp1D99 in IFNAR/
mice was largely restored and virus titers reached about 104–
105 pfu/g tissue in several organs after only 36 h (ﬁgures 5A–
5D). These data strongly suggest that nsp1 has a pivotal role in
counteracting type I IFN host responses and provide an
explanation for the rapid clearance of MHV-nsp1D99 in wild-
type mice. Interestingly, liver damage, measured as alanine 2-
oxoglutarate-aminotransferase (ALT) levels in serum, was not
yet detectable in MHV-nsp1D99–infected IFNAR/ mice at
36 h p.i. (Figure 5E). At 72 h p.i., MHV-nsp1D99 reached titers
and ALT levels in IFNAR/ mice comparable to those
observed in MHV-A59–infected IFNAR/ mice at 36 h p.i.,
demonstrating that MHV-nsp1D99 replication in IFNAR/ is,
although with slower kinetics, restored.
Immunization with the MHV nsp1 Deletion Mutant
Protects against Homologous and Heterologous Virus
Challenge
The phenotypic analysis of MHV-nsp1D99 revealed a
number of features that are advantageous for live attenuated
vaccines. MHV-nsp1D99 grows to high titers in cell culture,
infects pAPCs, replicates almost exclusively in secondary
lymphoid organs, and is strongly attenuated in vivo. To assess
the potential of MHV-nsp1D99 as an attenuated live vaccine,
we replaced accessory gene 4 of MHV-nsp1D99 and wild-type
MHV-A59 by a gene encoding a fusion protein of the
immunodominant cytotoxic T lymphocyte (CTL) epitope
(KAVYNFATC) of the lymphocytic choriomeningitis virus
(LCMV) and the enhanced green ﬂuorescent protein (GP33-
GFP) [29]. The resulting recombinant viruses, MHV-nsp1D99-
GP33-GFP and MHV-GP33-GFP, were used to infect C57BL/6
mice with different doses (50 and 5,000 pfu, intraperitoneal),
and CD8þ T cell responses were assessed using ﬂow
cytometry–based detection of intracellular IFN-c following
antigen-speciﬁc short-term in vitro restimulation. As shown
in Figure 6A and 6B, infection with as few as 50 pfu of MHV-
nsp1D99-GP33-GFP elicited strong CD8þ T cell responses
Figure 2. Construction and In Vitro Analysis of MHV-nsp1D99
(A) Schematic representation of the MHV-nsp1D99 genome organization.
The replicase gene, comprised of open reading frames (ORFs) 1a and 1b,
is depicted together with viral proteinase cleavage sites (arrowheads)
that separate nsps 1–16. The 99-nt deletion within the nsp1-coding
region of MHV-nsp1D99 is illustrated on the nucleotide and amino acid
level. The arrowhead (far right) indicates the nsp1/nsp2 cleavage site.
(B–E) Growth kinetics of MHV-nsp1D99– or MHV-A59–infected (MOI¼ 1)
murine 17Clone1 cells (B), inflammatory macrophages (C), bone marrow–
derived cDCs (D), and ex vivo cDCs (E). Experiments (C–E) were
performed with cells obtained from C57BL/6 mice. Results represent
the mean 6SD of two independent experiments. Statistical analysis was
performed using Student’s t-test (n.s., p . 0.05).
doi:10.1371/journal.ppat.0030109.g002
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against both the H2-Db–restricted GP33 and the H2-Kb–
restricted MHV S598 epitope.
To assess the level of protection against homologous MHV-
A59 challenge, groups of C57BL/6 mice were immunized
(5,000 pfu) with MHV-nsp1D99-GP33-GFP, MHV-GP33-GFP,
or treated with PBS. Sixteen days p.i., mice were challenged
with wild-type MHV (5,000 pfu) and viral titers were
determined 5 d post challenge infection. Viral titers were
below the limit of detection in MHV-nsp1D99-GP33-GFP–
and MHV-GP33-GFP–immunized mice (Figure 6C). Together
with the absence of elevated liver enzyme values in immu-
nized mice (Figure 6D), these data indicate that vaccination
with the attenuated MHV nsp1 mutant provides complete
protection against homologous virus challenge.
The reverse genetic system facilitates incorporation of
antigens derived from other infectious organisms. In order to
determine whether the attenuated nsp1 mutant virus could
confer protection against heterologous virus infection, MHV-
nsp1D99-GP33-GFP–immunized C57BL/6 mice were chal-
lenged after 4 wk with LCMV (200 pfu, intravenous). LCMV
titers in spleens were signiﬁcantly reduced both in mice
vaccinated with MHV-GP33-GFP and the attenuated MHV-
nsp1D99-GP33-GFP virus (Figure 6E). Remarkably, only 50
pfu of nsp1 mutant virus expressing the GP33 epitope were
Figure 3. MHV-nsp1D99 Is Highly Attenuated In Vivo
C57BL/6 mice were infected intraperitoneally (A–E) or intracranially (F) with the indicated dose of MHV-nsp1D99 or MHV-A59. Viral titers in spleens (A)
and livers (B) were determined at the indicated time points p.i. (C) Liver enzyme ALT values were measured at the indicated time points p.i. (D)
Hematoxylin and eosin–stained liver sections of C57BL/6 mice infected intraperitoneally with 5,000 pfu of MHV-nsp1D99 or MHV-A59. The time points
of analysis p.i. are indicated. (E) Groups of four mice were either untreated (mock) or infected (intraperitoneally) with 53 106 pfu of MHV-nsp1D99 or
MHV-A59. The weight was monitored daily.  denotes death of mice. (F) Survival of mice (three per group) infected with 20,000 pfu (intracranially) of
MHV-nsp1D99 or MHV-A59. Mice with severe weight loss (.25%) were defined as moribund and sacrificed. Results (A–C) and (E) represent the mean
6SD of at least three individual mice per time point.
doi:10.1371/journal.ppat.0030109.g003
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sufﬁcient to achieve a reduction of LCMV titers by more than
4 orders of magnitude, indicating that nsp1 mutant viruses
are well-suited to serve as attenuated recombinant virus
vectors against heterologous viral infections.
Discussion
The rational design of live attenuated viral vaccines is
greatly facilitated by the identiﬁcation and targeting of
pathogenicity factors. This study demonstrates an unprece-
dented level of attenuation of a murine coronavirus through
a 99-nt deletion in nsp1. The nsp1 mutant virus was rapidly
cleared in mice and did not induce clinical signs of disease in
immunocompetent mice. These ﬁndings in the murine
coronavirus model demonstrate that nsp1 is a major
pathogenicity factor. In a stepwise approach, we made use
of these observations to provide a blueprint for the
construction and evaluation of live attenuated coronavirus
vaccines encoding a truncated nsp1.
The presented results indicate that nsp1 plays a crucial role
in the MHV life cycle by interfering with host innate immune
responses. In accordance with the recent report by Kamitani
et al. [18], we observed reduced reporter gene expression in
transient nsp1 expression studies. The suggestion that SARS-
CoV nsp1 may play a role in SARS-CoV pathogenesis by
promoting host cell mRNA degradation [18] has now received
support through the analysis of a coronavirus nsp1 mutant in
a murine model. The MHV nsp1 mutant phenotype led us to
conclude that nsp1 mainly affects IFN signaling pathways or
other downstream events. The inﬂuence on IFN-a induction
appears to be limited. These conclusions are based on several
observations. First, the analysis of IFN-a production by pDCs
and cDCs revealed no signiﬁcant differences between wild-
type and nsp1 mutant virus infections. Second, treatment of
macrophages with IFN-a revealed a more efﬁcient reduction
of MHV-nsp1D99 replication compared with that of wild-type
MHV. Finally, and most strikingly, IFNAR/mice were highly
permissive for the mutant virus, and organ titers almost
reached those of wild-type MHV-infected IFNAR/ mice.
Nevertheless, it should be noted that the nsp1 mutant virus
replication was still slightly delayed in IFNAR/ mice.
Therefore, further studies are required to deﬁne molecular
target(s) and the precise function(s) of coronavirus nsp1.
Likewise, further studies are required to assess the impact of
other coronaviral gene products on coronavirus pathogenic-
ity. Recent reports indicate that coronaviruses most likely
express a number of proteins, such as MHV and SARS-CoV
nucleocapsid proteins, and SARS-CoV ORF3b and ORF6
proteins, that may interact with innate immune responses
[19,20]. Also, the coronavirus replicase gene may harbor
additional functions that play a role in virus–host interac-
tions. It has been shown that the MHV and SARS-CoV nsp2
proteins [30], and the highly conserved ADP-ribose-199-
monophosphatase activity [31] encoded in nsp3, are both
dispensable for virus replication in tissue culture, and that a
single point mutation in the MHV nsp14 confers a strong
attenuation of MHV in mice [32]. Clearly, the murine model,
with MHV as a natural mouse pathogen, will be highly
Figure 4. Effect of nsp1 on IFN-a Production and Signaling
C57BL/6 bone marrow–derived (A) or primary (B) splenic cDCs or pDCs were infected with MHV-nsp1D99 or MHV-A59 at an MOI of 1. IFN-a secreted
into cell culture supernatants was determined by ELISA at the indicated time points. Bone marrow–derived cDCs (C) or inflammatory macrophages (D)
from 129Sv mice were treated with 50, 200, 500, or 1,000 U IFN-a/100,000 cells or left untreated. Four hours later, cells were infected with MHV-nsp1D99
or MHV-A59 (MOI¼ 1). Twelve hours p.i., virus titers in culture supernatants were determined by plaque assay. Representative experiments out of two
(A, B) or the mean 6 SD of two independent experiments (C, D) are shown. Statistical analysis was performed using Student’s t-test (***, p, 0.001; **, p
, 0.01; *, p , 0.05; n.s., p . 0.05).
doi:10.1371/journal.ppat.0030109.g004
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advantageous in the examination of this issue, because it
allows the use of well-characterized inbred and transgenic
mice in combination with well-established immunological
techniques required to assess the full range of coronavirus–
host interactions.
The most remarkable ﬁnding of this study is the level of
attenuation of the nsp1 mutant virus and its restricted
replication in secondary lymphoid organs. It may well be that
other coronaviral nsp1 molecules exert similar functions as
the MHV nsp1. The coronavirus nsp1 has been suggested as a
group-speciﬁc marker to differentiate group 1 coronaviruses
from group 2a/2b coronaviruses [22]. Our transient nsp1
expression data indeed support the notion that SARS-CoV
and MHV may encode evolutionarily conserved nsp1 homo-
logs [22,23]. Nevertheless, further in vivo studies are required
to determine whether the group 2b SARS-CoV nsp1 is indeed
a functional equivalent to the structurally highly conserved
group 2a nsp1 molecules encoded by MHV, bovine corona-
virus, porcine hemagglutinating encephalomyocarditis virus,
HCoV-OC43, and HCoV-HKU1. Likewise, it will be impor-
tant to clarify in vivo, whether, despite the apparent lack of
any sequence homology [22,23], the nsp1 of group 1
coronaviruses (e.g., HCoV-229E) may represent a functional
correlate to the nsp1 of group 2a/2b coronaviruses. Recent
progress in the establishment of suitable mouse models for
SARS-CoV [33–35] and HCoV-229E [36] will enable research-
ers to address these questions in future studies.
The chosen attenuation strategy has resulted in the
generation of a recombinant virus that fulﬁlls important
criteria of a live virus vaccine candidate: (i) growth to high
titers in cell culture, which facilitates vaccine production, and
(ii) generation of immunological memory that mediates
efﬁcient protection against viral challenge. One important
aspect of protection against viral infections is the induction
of speciﬁc cytotoxic T cells by pAPCs in secondary lymphoid
organs [14]. A number of coronaviruses, such as MHV, HCoV-
229E, feline infectious peritonitis virus, and SARS-CoV, have
been shown to infect pAPCs and to replicate in the secondary
lymphoid organs [27,37–42]. Because of their pronounced
tropism for pAPCs and the induction of strong CTL
responses, we propose that coronaviruses represent promis-
ing vectors for the expression of heterologous antigens. The
identiﬁcation of nsp1 as a major pathogenicity factor will
signiﬁcantly increase the safety of coronavirus-based vectors
Figure 5. nsp1-Dependent Attenuation Is Reversed in IFNAR/ Mice
IFNAR/ or wild-type 129Sv mice were infected intraperitoneally with 500 pfu of MHV-nsp1D99 or MHV-A59. At the indicated time points p.i., viral titers
in livers (A), spleens (B), peritoneal exudates cells (PEC) (C), and lungs (D) were determined. (E) ALT values in serum were measured at the indicated time
points p.i. Horizontal lines represent means with values from individual mice shown as open squares (MHV-A59) or filled triangles (MHV-nsp1D99) from
two experiments with a total of three to six mice. Statistical analysis was performed using Student’s t-test (***, p , 0.001; *, p , 0.05; n.s., p . 0.05).
doi:10.1371/journal.ppat.0030109.g005
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[43]. For example, the deletion of accessory genes (i.e., not
replicase or structural genes) has been described for some
coronaviruses to confer attenuation in the natural host [44–
46], and the deletion of the structural envelope protein E has
resulted in the development of replication-competent, but
propagation-deﬁcient, coronavirus vectors [47,48]. Now, with
an accompanying deletion in the nsp1-coding sequence, such
vectors would be considered ‘‘recombination proof’’, because
the deletions are located at opposite genomic regions (i.e.,
within the replicase gene at the 59 end and within the
structural gene region at the 39 end of the coronavirus
genome), which make the reconstruction of virulent viruses
by recombination unlikely. We therefore suggest that
accessory gene, E gene, and partial nsp1 gene deletions will
result in particular safe vectors with the potential to express
multiple heterologous antigens [40,49].
Taken together, our results describe a novel type of
coronavirus vaccines based on impaired function of a
replicase gene product. We expect that our approach is
applicable to most, if not all, mammalian coronaviruses and
that it will enable the development of long-desired live
attenuated vaccines for important coronavirus-induced dis-
eases in humans and animals.
Materials and Methods
Mice and cells. C57BL/6 mice were obtained from Charles River
Laboratories (http://www.criver.com/). 129Sv and type I IFN receptor-
deﬁcient mice (IFNAR/) [28] were obtained from the Institut fu¨r
Labortierkunde (University of Zu¨rich) and bred in our facilities. All
mice were maintained in individually ventilated cages and were used
between 6 and 9 wk of age. All animal experiments were performed in
accordance with the Swiss Federal legislation on animal protection.
MC57, BHK-21, L929, 293, and CV-1 cells were purchased from the
European Collection of Cell Cultures (http://www.ecacc.org.uk/).
D980R cells were a kind gift from G. L. Smith, Imperial College,
London, United Kingdom. 17Clone1 cells were a kind gift from S. G.
Sawicki, Medical University of Ohio, Toledo, Ohio, United States.
BHK-MHV-N cells, expressing the MHV-A59 nucleocapsid protein
under the control of the TET/ON system (Clontech, http://www.
clontech.com/), have been described previously [24]. All cells were
Figure 6. MHV-nsp1D99-GP33-GFP and MHV-GP33-GFP Elicit Strong CTL Responses and Protect Mice from Homologous and Heterologous Viral
Infections
(A, B) Groups of three C57BL/6 mice were immunized with the indicated doses of MHV-nsp1D99-GP33-GFP or MHV-GP33-GFP. IFN-c–secreting CD8þ
splenocytes were determined 8 d post immunization following short-term in vitro restimulation with GP33 or S598 peptide. Values in (A) represent the
percentage 6SD of IFN-c–secreting CD8þ T cells restimulated with GP33 or S598; values in (B) represent the absolute numbers of CD8þ IFN-cþ cells 6SD
(n¼ 6 for GP33, n ¼ 3 for S598). Pooled data from two separate experiments are shown.
(C, D) Groups of three mice were immunized with 5,000 pfu of the indicated virus or PBS-treated and 14 d later challenged with 5,000 pfu of wild-type
MHV-A59. At 5 d post challenge, viral titers in liver and spleen were determined (C) and ALT values (D) were measured. Data in graphs (C) and (D)
represent means 6SD from one representative experiment. n.d., not detected.
(E) Protection against heterologous viral challenge. Groups of four C57BL/6 mice have been immunized with the indicated viral doses or PBS-treated
and 28 d later challenged with 200 pfu of LCMV-WE. At 4 d post challenge, viral titers in spleens were determined. Data in graph represent means 6SD
from two pooled experiments with a total of eight mice per group. Statistical analysis was performed using Student’s t-test (***, p , 0.001; **, p, 0.01;
n.s., p . 0.05).
doi:10.1371/journal.ppat.0030109.g006
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maintained in minimal essential medium supplemented with fetal
bovine serum (5%–10%) and antibiotics.
Isolation of dendritic cells and macrophages, ﬂow cytometry, and
antibodies. Murine cDCs and pDCs were obtained from spleens of
C57BL/6, 129Sv, or IFNAR/ mice following digestion with collage-
nase type II (Gibco-BRL, http://www.invitrogen.com/) for 20 min at 37
8C. Cells were resuspended in PBS supplemented with 2% FCS and 2
mM EDTA and overlaid on 20% Optiprep density gradient medium
(Sigma-Aldrich, http://www.sigmaaldrich.com/). After centrifugation
at 700g for 15 min, low density cells were depleted of CD3- and CD19-
positive cells using DYNAL magnetic beads according to the
instructions of the manufacturer (Invitrogen, http://www.invitrogen.
com/). The DC-enriched preparations were stained with a-PDCA-1, a-
CD11b, and a-CD11c, and the distinct pDC and cDC populations
were sorted using a FACS ARIA (BD Biosciences, http://www.
bdbiosciences.com/) sorter. Purity of both cell preparations was
always .98%.
Murine bone marrow–derived cDCs or pDCs were generated by 6
to 7 d of culture with either granulocyte-monocyte colony stimulating
factor (GM-CSF)-containing supernatant from the cell line X63-GM-
CSF (kindly provided by Antonius Rolink, University of Basel, Basel,
Switzerland) or Flt3-L (R&D Systems, http://www.rndsystems.com/) at
20 ng/ml, respectively. Bone marrow–derived cDCs were further
puriﬁed using Optiprep density gradient centrifugation. Bone
marrow–derived pDCs were puriﬁed using the mouse pDC isolation
kit (Miltenyi Biotec, http://www.miltenyibiotec.com/) adapted for the
isolation of in vitro–derived pDCs by adding CD11b-biotin to the
negative selection cocktail. Antibodies used in this study were
purchased from BioLegend (http://www.biolegend.com/): CD11c-PE,
B220-APC, CD11b-FITC; or from Miltenyi Biotec: mPDCA-1-FITC
and CD11c-APC. Thioglycolate-elicited macrophages were collected
from the peritoneal cavity of mice and cultured at 4 3 105 cells per
well in DMEM (with 10% FCS, L-glutamine, and penicillin/strepto-
mycin) for 2 h at 37 8C. Non-adherent cells were removed by washing
with cold PBS.
Recombinant DNA and viruses. LCMV-WE strain, originally
obtained from F. Lehmann-Grube (Hamburg, Germany), was propa-
gated on L929 cells. MHV A59 was generated from a molecularly
cloned cDNA [24] based on the Albany strain of MHV A59.
Coronaviruses and recombinant vaccinia viruses were propagated,
titrated, and puriﬁed as described [24,50,51].
Mutant vaccinia viruses are based on the recombinant vaccina
virus vMHV-inf-1 (containing the full-length MHV-A59 cDNA) and
were generated using our reverse genetic system as described
previously [24]. Brieﬂy, the gene to be mutated was replaced by the
Escherichia coli guanine-phosphoribosyltransferase (GPT) gene
through vaccinia virus–mediated homologous recombination, and
GPT-positive clones were selected by three rounds of plaque
puriﬁcation on CV-1 cells in the presence of xanthine, hypoxanthine,
and mycophenolic acid (GPT-positive selection) [50]. In a second
round, the GPT gene was replaced by the mutated gene, and GPT-
negative clones, containing the mutated gene, were selected by three
rounds of plaque puriﬁcation on D980R cells in the presence of 6-
thioguanine (GPT-negative seletion) [50]. To construct the recombi-
nant vaccinia virus encoding the MHV-nsp1D99 cDNA, the 59 end of
the MHV-A59 cDNA in vMHV-inf-1 was replaced by GPT using the
plasmid pRec4. This plasmid is based on pGPT-1 [50], and the GPT
gene is ﬂanked to its left by 500 bp of vaccinia DNA and to its right by
an internal ribosomal entry sequence (IRES) followed by MHV-A59
nts 952-1315. The GPT-negative selection was carried out using the
plasmid pRec15. This plasmid contains 250 bp of vaccinia DNA
followed by the bacteriophage T7 RNA polymerase promoter, one G
nucleotide, and MHV nts 1–828 linked to MHV nts 928-1315. To
replace the MHV-A59 accessory gene 4 in vMHV-inf-1 and vMHV-
nsp1D99 by a gene encoding a fusion protein of EGFP and the LCMV-
derived CTL epitope KAVYNFATC (GP33-GFP) [29], the plasmid
pRec8 was used for recombination with vaccinia viruses vMHV-inf-1
and vMHV-nsp1D99 . This plasmid contains the GPT gene ﬂanked to
its left by MHV nts 27500–27967 and to its right by MHV nts 28265–
28700. GPT-negative selection was carried out using the plasmid
pRec9. This plasmid contains MHV bp 27500–27967, the GP33-GFP
gene, and MHV nts 28265–28700. Further cloning details, plasmid
maps, and sequences are available from the authors upon request.
Recombinant coronaviruses were rescued from cloned cDNA using
puriﬁed vaccinia virus DNA as template for the in vitro transcription
of recombinant MHV genomes as described [51].
The ﬁreﬂy luciferase (FF-Luc) plasmid for monitoring IFN-b
promoter activation (p125-Luc) was kindly provided by Takashi
Fujita, Tokyo Metropolitan Institute of Medical Science, Japan [52].
The FF-Luc reporter construct for monitoring ISRE activation (p(9–
27)4tkD(39)lucter) [53] was kindly provided by Stephen Goodbourn,
St. George’s Hospital Medical School, London, UK. The control
plasmid pRL-SV40 (Promega, http://www.promega.com/) encodes the
renilla luciferase (REN-Luc) gene under control of the constitutive
SV40 promoter. The negative control expression plasmid contained
the reading frame of the N-terminus of the human MxA protein. To
construct the coronavirus nsp1 expression plasmids, the MHV nts 1–
951 (pMHV-nsp1), MHV nts 1–902 (pMHV-D49), MHV nts 1–851
(pMHV-D100), HCoV-229E nts 293–625 (pHCoV-229E-nsp1), and
SARS-CoV nts 265–804 (pSARS-CoV-nsp1) were ampliﬁed by stand-
ard PCR techniques and cloned downstream of a CMV promoter
between the SmaI and XhoI sites of the eukaryotic high-level
expression plasmid pI.18 (kindly provided by Jim Robertson,
National Institute for Biological Standards and Control, Hertford-
shire, UK).
Transient transfections and reporter gene assays. Subconﬂuent
cell monolayers of 293 cells seeded in 12-well plates were transfected
with 250 ng p125-Luc reporter plasmid, 50 ng pRL-SV40, and 1 lg of
expression plasmid in 200 ll of OPTIMEM (Gibco-BRL) containing
3.9 ll of Fugene HD (Roche, http://www.roche.com). At 8 h post
transfection, cells were induced with either 0.2 lg of viral ssRNA
containing 59 triphosphates [54] (p125-Luc), 2.5 lg of poly(I:C)
(Sigma), or 500 U/ml IFN-a (p(9–27)4tkD(39)lucter), or left unin-
duced. After an incubation period of 16 h, cells were harvested and
lysed in 100 ll of Reporter Lysis Buffer (Promega). An aliquot of 10 ll
lysate was used to measure luciferase activity as decribed by the
manufacturer (Promega).
Virus infections, determination of virus titers, and liver enzyme
values. Mice were injected intraperitoneally or intracranially with
indicated pfu of MHV A59 or intravenously with the indicated pfu of
LCMV and sacriﬁced at the indicated time points. Organs were stored
at 70 8C until further analysis. Blood was incubated at RT to
coagulate, centrifuged, and serum was used for ALT measurements
using a Hitachi 747 autoanalyzer (http://www.hitachi.com/). Peritoneal
exudates cells (PECs) were isolated from the peritoneal cavity by
ﬂushing with 4 ml of ice-cold PBS. MHV titers were determined by
standard plaque assay using L929 cells. LCMV titers in the spleens
were determined 4 d after intravenous challenge in an LCMV
infectious focus assay as previously described [55].
Histology, IFN-a ELISA, IFN-a treatment. Organs were ﬁxed in 4%
formalin and embedded in parafﬁn. Sections were stained with
hematoxylin and eosin. Images were acquired using a Leica DMRA
microscope (Leica, http://www.leica.com/) with a 253/0.65 NA objec-
tive (total magniﬁcation, 3162). Images were processed using Adobe
Photoshop (Adobe Systems, http://www.adobe.com). Mouse IFN-a
concentration in cell culture supernatants was measured by ELISA
(PBL Biomedical Laboratories, http://www.interferonsource.com/)
according to the manufacturer’s instructions. IFN-a treatment of
cells prior to MHV infection was performed using universal type I
IFN (IFN-aA/D, Sigma).
Intracellular cytokine staining. Speciﬁc ex vivo production of IFN-
c was determined by intracellular cytokine staining. Organs were
removed at the indicated time points following infection with
recombinant MHV. For intracellular cytokine staining, single cell
suspensions of 13 106 splenocytes were incubated for 5 h at 37 8C in
96-well round-bottom plates in 200 ll of culture medium containing
25 U/ml IL-2 and 5 lg/ml Brefeldin A (Sigma). Cells were stimulated
with phorbolmyristateacetate (PMA, 50 ng/ml) and ionomycin (500
ng/ml) (both purchased from Sigma) as positive control or left
untreated as a negative control. For analysis of peptide-speciﬁc
responses, cells were stimulated with 106 M GP33 peptide or 104 M
MHV S598 peptide. The percentage of CD8þ T cells producing IFN-c
was determined using a FACSCalibur ﬂow cytometer (BD Bioscien-
ces). Both S598 (RCQIFANI) and GP33 (KAVYNFATC) peptides were
purchased from Neosystem (http://www.neomps.com/).
Statistical analysis. All statistical analyses were performed with
Prism 4.0 (GraphPad Software, http://www.graphpad.com/). Data were
analyzed with the paired Student’s t-test assuming that the values
followed a Gaussian distribution. A p-value of , 0.05 was considered
signiﬁcant.
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